Amy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor Therapy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.

Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.
Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.

Faculty/Planner
Hossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.
Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.

Faculty/Planner
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.